Skip to main content
Premium Trial:

Request an Annual Quote

Myriad Genetics Wins $14.2M NIH Contract to Analyze Host-Pathogen Protein Interactions

NEW YORK, July 8 (GenomeWeb News) - Myriad Genetics has won $14.2 million from the National Institute of Allergy and Infectious Diseases to analyze pathogen-host protein interactions using high-throughput proteomics.

 

Under the five-year contract, Salt Lake City-based Myriad will use its yeast two-hybrid technology, bioinformatics, and DNA sequencing to conduct proteome-wide analyses of protein interactions between humans and selected pathogens. Myriad also plans to validate these interactions by other methods, such as microbial gene knockout and siRNA.

 

Myriad will have the rights to commercialize diagnostic and therapeutic targets discovered in the project. All protein interaction and validation data will be made publicly available through the Proteomics Research Program Administrative Center.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.